Pharmacies to shun quasi-drugs

Published: 2003-04-10 06:57:00

Updated: 2003-04-10 06:57:00

Pharmaceutical business sources say that many pharmacies has little interest in handling quasi-drugs due to their concentrated efforts to acquire more prescriptions, while quasi-drug makers are also shunning the pharmacy market in fear of protracted settlement period, spoiled selling, and higher ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK